After raising nearly $330m this year, via a financing and IPO, the company is gearing up for a first-in-human trial using its platform technology.

With 46 initial public offerings in the US by drug developers so far – including recent launches by Kymera, Inhibrx and Harmony – 2020 will easily beat last year’s 50 IPOs. In follow-on offerings and VC deals, newly public Schrodinger raised $346.5m and Tango’s $50m equity financing.

Company keeps on track on for 2020 earnings target despite pandemic's hit to general medicines and vaccines sales.

Kymera will receive $150m upfront from Sanofi in a deal the big pharma views as an opportunity to develop a breakthrough oral drug for atopic dermatitis and other conditions.